




## STATE MEDICAID P&T COMMITTEE MEETING

Thursday, February 20, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 114



# MINUTES

### Committee Members Present:

Kort Delost, R.Ph.

Ellie Brownstein, M.D.

Julia Ozbolt, M.D.

Lisa Hunt, R.Ph.

Jameson Rice, Pharm.D.

### Committee Members Excused:

Beth Johnson, R.Ph.

Roger Martenau, M.D.

Bernadette Kiraly, M.D.

Elizabeth Young, Pharm.D.

### Dept. of Health/Div. of Health Care Financing Staff Present:

Trevor Smith, Pharm.D.

Richard Sorenson, RN

### University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

### Other Individuals Present:

Scott Larson, BMS

Sumar Buda, Purdue

Paul Bonham, NovoNordisk

Chad Burnham, Select Health

Meeting conducted by: Kort Delost

---

1. **Review and Approval of December and January Minutes:** Julia Ozbolt made a motion to approve December minutes, Ellie Brownstein seconded the motion, all in favor. Ellie Brownstein made a motion to approve January minutes, Jameson Rice seconds the motion, all in favor.
2. **Housekeeping:** Utah Medicaid is preparing a PDL for 2014 that should be released soon. The draft is posted on the Medicaid website.
3. **Drug Utilization Review (DUR) Board update:** No DUR update this month as Robyn Seely is attending the ADURS conference.
4. **Short Acting Opioid Agents:** Melissa Archer presented a review of short acting opioid agents. Seventeen agents were presented for review. Peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

## **5. No Public comment**

## **6. Committee discussion**

- a. Lisa Hunt clarified to the committee about the quantity limits on the short acting agents.
- b. Lisa Hunt said that the agents for opioid dependence (Suboxone) have already been reviewed, and will not require a decision from the committee. In addition, agents for cough will not require a decision.
- c. Jameson Rice asked about the any adverse effects between Nucynta and other older agents. Melissa Archer said that there was only one study that compared Nucynta vs six other agents, and there was no difference.
- d. Jameson Rice questioned if the rapid onset fentanyl products (Actiq) would be included in the discussion. This drug requires the pharmacy a training program with the pharmacy and is tightly controlled. This drug will be included in discussion.
- e. Lisa Hunt asked about tramadol prescriptions prescribed by Naturopathic providers. She said that there is a bill in the legislature to allow these providers to dispense.
- f. Kort Delost questioned about the meperidine usage, as there are a high number of claims, and it is not indicated for use as an analgesic by the American Pain Society. Additional discussion about how the claims may be from dentists who use the medication as a pre-treatment for children.
- g. Discussion about codeine use among small children can be a problem as a safety issue.
- h. Ellie Brownstein makes a motion that the class of short acting opioid agents are equally safe and effective at equipotent dosing. Julia Ozbolt seconds the motion. All in favor.
- i. Lisa Hunt asked about meperidine and codeine agents for young children, and asked if the committee wants to put any age limits on those agents. The committee requested that the DUR board look at the issue.
- j. Ellie Brownstein made a motion to include liquid formulations as a preferred agent in the PDL. Julia Ozbolt seconded the motion. All in favor.
- k. Kort Delost asked if other dosage forms would be included like injectables, sprays, and others. They would be included, but not necessarily as preferred agents.
- l. Jameson Rice made a motion to include one rapid onset opioid agent in the PDL.

Ellie Brownstein seconded the motion. All in favor.

- m. Jameson Rice brings up non oral dosage formulations and if they will be included in the PDL. They can be listed as non-preferred agents, and the DUR board can put additional restrictions on them
  - n. Lisa Hunt explained that Butalbital agents have a clinical PA on them.
  - o. Kort Delost makes a motion that the short acting opioid agents are equally safe and effective, either in single use or in combination in equipotent dosing for inclusion in the PDL. Jameson Rice seconds the motion. All in favor.
7. Next meeting is scheduled for March 20, 2014. Antiemetic agents and appetite stimulant agents will be discussed.
8. Ellie Brownstein makes a motion to adjourn. Lisa Hunt seconds, all in favor.

---

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)